Discovering A Potential Drug Target and Biomarker for Cancer (G406939)

Discovering A Potential Drug Target and Biomarker for Cancer

MicroRNA 147a (miRNA-147a) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. This molecule has unique characteristics that make it an attractive target for drug development due to its potential to alter the expression of genes involved in cell growth, apoptosis, and inflammation.

The discovery of miRNA-147a began in 2006 when researchers identified a small non-coding RNA molecule that was expressed in various tissues and at different stages of development. The molecule was later named miRNA-147a due to its unique sequence and its ability to interact with other molecules known as microRNAs.

Since its discovery, miRNA-147a has been shown to play a critical role in various biological processes, including cell growth, apoptosis, and inflammation. This molecule has been shown to regulate the expression of genes involved in cell cycle progression, apoptosis, and cell signaling pathways.

One of the most significant functions of miRNA-147a is its role in cell apoptosis. Apoptosis is a natural process that is essential for the development and maintenance of tissues and organs. MiRNA-147a has been shown to regulate the expression of genes involved in apoptosis. , including the Bcl-2 gene. Bcl-2 is a protein that has been shown to prevent apoptosis and promote survival. By regulating the expression of Bcl-2, miRNA-147a has been shown to promote apoptosis, which is a critical process for removing damaged or dysfunctional cells from the body.

Another function of miRNA-147a is its role in cell signaling pathways. Signaling pathways are critical for the regulation of cellular processes, including cell growth, apoptosis, and inflammation. MiRNA-147a has been shown to regulate the expression of genes involved in several signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway. These pathways are involved in the regulation of cellular processes that are critical for tissue development, maintenance, and function.

MiRNA-147a has also been shown to play a role in the regulation of cell cycle progression. The cell cycle is the process by which cells divide and replicate their genetic material. MiRNA-147a has also been shown to regulate the expression of genes involved in cell cycle progression, including the p21 gene. The p21 gene is a tumor suppressor gene that has been shown to play a critical role in the regulation of cell cycle progression and apoptosis.

In addition to its role in cell apoptosis and cell signaling pathways, miRNA-147a has also been shown to regulate the expression of genes involved in inflammation. Inflammation is a critical response of the immune system to harmful stimuli, including cancer cells. MiRNA-147a has been shown to regulate the expression of genes involved in inflammation, including the turn gene (ASC/N cost gene) and the nuclear factor kappa B (NF-kappa-B) gene.

MiRNA-147a has also been shown to have potential as a drug target. The use of drugs to target miRNA-147a has been shown to be effective in treating various diseases, including cancer. For example, studies have shown that inhibiting the expression of miRNA -147a using small interfering RNA (siRNA) can be an effective way to treat cancer. This is because siRNA can target specific genes and silence their expression, including miRNA-147a.

In conclusion, miRNA-147a is a non-coding RNA molecule that has unique characteristics that make it an attractive target for drug development due to its potential to alter the expression of genes involved in cell growth, apoptosis, and inflammation. The discovery of miRNA -147a has

Protein Name: MicroRNA 147a

The "MIR147A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR147A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG